Literature DB >> 26136794

The T.A.R.Ge.T. project: a regional program to reduce hip fracture in elderly patients. Main results of retrospective phase.

Simone Parri1, Luisella Cianferotti1, Gemma Marcucci1, Giorgio Gronchi2, Carla Rizzuti3, Emanuela Colli1, Beatrice Manetti4, Walter Naldoni4, Maria Luisa Brandi1.   

Abstract

The Tuscany Region was the first Italian Region to initiate a program for the prevention of hip fractures in over 65 year old. The T.A.R.Ge.T. project "Appropriate treatment of geriatric re-fractures in Tuscany" (Trattamento Appropriato delle Rifratture Geriatriche in Toscana), which is still on-going, includes a preliminary phase (2009-2010) for baseline analysis and education of the participating centers and a 4-year-prospective phase (2011-2014). The monitoring system is performed horizontally analyzing 5 different flows: SDO (Performance Hospitalization), SPF (Pharmaceutical Distribution Dataset), FED (Direct Distribution Dataset), SAA (Registry of Patients), SPA (Specialized Outpatient) flows. In this review will be shown some of the most important results of analyzes of the retrospective phase. Between 2006 and 2011 only 26% of hip fractured patients has being treated with anti-osteoporotic drugs. The percentage of treatment increases 10% after the second fracture. Until 2011 there wasn't in Tuscany a prevention program of bone fragility; patients were treated with specific treatment only in severe cases: this phenomenon implies that mortality and re-fracture are higher on treated patients than in patients who did not have any kind of treatment. The treated patients are the most severe and therefore they have a higher risk of death and re-fracture.

Entities:  

Keywords:  anti-fracture drugs; fractures; hip; institutional database; persistence; re-fractures

Year:  2015        PMID: 26136794      PMCID: PMC4469224          DOI: 10.11138/ccmbm/2015.12.1.034

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  12 in total

1.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Authors:  R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

2.  Adherence to therapeutic and diagnostic recommendations in patients with femur fracture and at risk of re-fracture or death: results of an analysis of administrative databases.

Authors:  L Degli Esposti; L Sinigaglia; M Rossini; S Adami; C Cagnoni; C Magliaro; C Veronesi; S Buda; S Minisola
Journal:  Reumatismo       Date:  2012-03-16

3.  Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Authors:  Jean-Yves Reginster; Eric Abadie; Pierre Delmas; René Rizzoli; Willard Dere; Philippevan der Auwera; Bernard Avouac; Maria-Luisa Brandi; Anastasia Daifotis; Adolfo Diez-Perez; Gonzalo Calvo; Olof Johnell; Jean-Marc Kaufman; Gottfried Kreutz; Andrea Laslop; Fritz Lekkerkerker; Bruce Mitlak; Per Nilsson; John Orloff; Mary Smillie; Andrew Taylor; Yannis Tsouderos; Dominique Ethgen; Bruno Flamion
Journal:  Osteoporos Int       Date:  2005-08-10       Impact factor: 4.507

4.  Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of.

Authors:  Umberto Tarantino; Sergio Ortolani; Luca Degli Esposti; Chiara Veronesi; Stefano Buda; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

5.  The TARGET project in Tuscany: the first disease management model of a regional project for the prevention of hip re-fractures in the elderly.

Authors:  Prisco Piscitelli; Maria Luisa Brandi; Ranuccio Nuti; Carla Rizzuti; Loredano Giorni; Valtere Giovannini; Alessia Metozzi; Daniela Merlotti
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

6.  The effect of osteoporotic treatment on the functional outcome, re-fracture rate, quality of life and mortality in patients with hip fractures: a prospective functional and clinical outcome study on 520 patients.

Authors:  Konstantinos G Makridis; Theofilos Karachalios; Vasilios A Kontogeorgakos; Leonidas S Badras; Konstantinos N Malizos
Journal:  Injury       Date:  2014-12-08       Impact factor: 2.586

Review 7.  Management of osteoporosis with PTH: treatment and prescription patterns in Europe.

Authors:  David Hosking; Carlos Gómez Alonso; Maria Luisa Brandi
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

Review 8.  Post-fracture management of patients with hip fracture: a perspective.

Authors:  O Bruyere; M-L Brandi; N Burlet; N Harvey; G Lyritis; H Minne; S Boonen; J-Y Reginster; R Rizzoli; K Akesson
Journal:  Curr Med Res Opin       Date:  2008-08-28       Impact factor: 2.580

9.  Antifracture drugs consumption in Tuscany Region before the Target Project: a valuable model for the analysis of administrative database.

Authors:  Prisco Piscitelli; Simone Parri; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

10.  Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Authors:  R Rizzoli; S Boonen; M-L Brandi; O Bruyère; C Cooper; J A Kanis; J-M Kaufman; J D Ringe; G Weryha; J-Y Reginster
Journal:  Curr Med Res Opin       Date:  2013-02-07       Impact factor: 2.580

View more
  2 in total

1.  The use of cholecalciferol in patients with hip fracture.

Authors:  Luisella Cianferotti; Simone Parri; Giorgio Gronchi; Roberto Civinini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

2.  The Use of Network Theory for Analyzing Switching Behaviors: Assessing Cognitive and Educational-Based Intervention for Promoting Health.

Authors:  Giorgio Gronchi
Journal:  Front Psychol       Date:  2018-06-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.